Enterprise Value

128.5M

Cash

34.47M

Avg Qtr Burn

-7.178M

Short % of Float

1.32%

Insider Ownership

3.98%

Institutional Own.

45.91%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ciforadenant (A2AR inhibitor) Details
Renal cell carcinoma, Cancer

Phase 2

Data readout

Mupadolimab (CPI-006) (Anti-CD73) Details
Renal cell carcinoma, Lung cancer, Cancer, Non-small cell lung carcinoma

Phase 2

Update

Mupadolimab + pembrolizumab Details
HPV+ oropharyngeal cancer, Head and neck cancer, Non-small cell lung carcinoma, Cancer

Phase 1b

Data readout

CPI-818 (ITK inhibitor) Details
Cutaneous T cell lymphoma, Lymphoma, Cancer, Blood cancer

Phase 1b

Data readout

Failed

Discontinued